Company news

Kiora Pharmaceuticals, Inc. news in 2026

Kiora Pharmaceuticals, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Kiora Pharmaceuticals In-Licenses Late-Stage, Oral Neuroprotective Calpain Inhibitor for Central Retinal Artery Occlusion (CRAO) with Planned Expansion into NAION; Asset Completed Phase 3 Clinical Trial in CRAO in Japan

October 29, 2026

Kiora Pharmaceuticals Appoints Keith J. Lane as Executive Vice President of Global Clinical Development and Regulatory Affairs

September 8, 2026

Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation

August 19, 2026

Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 7, 2026

Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium

July 1, 2026

Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model

June 18, 2026

Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 8, 2026

Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway

April 14, 2026

Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive Advisors

April 6, 2026

Kiora Pharmaceuticals Announces Management Team Changes

April 1, 2026

Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical Trials

March 25, 2026

Kiora Pharmaceuticals to Present at Oppenheimer's 36th Annual Healthcare Life Sciences Conference

February 19, 2026

Retinal Disease Expert Dr. Taiji Sakamoto Joins Kiora Pharmaceuticals' Scientific Advisory Board

January 27, 2026

Decks in 2026